FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095921647> ?p ?o ?g. }

• W3095921647 endingPage "002410" @default.
• W3095921647 startingPage "ejhpharm" @default.
• W3095921647 abstract "<h3>Objective</h3> Switching patients from the originator infliximab to a biosimilar is a measure to expand access to treatments and counteract its negative impact on healthcare budgets. However, industry-independent long-term studies on the effect of switching in real life to support the lack of switch-related problems in inflammatory bowel disease (IBD) patients are sparse, as are studies addressing infliximab pharmacokinetic behaviour. The objectives were to investigate the effectiveness and the pharmacokinetics of CT-P13 after switching from originator infliximab in a real-world population of IBD patients with a follow-up of 2 years. <h3>Method</h3> Prospective, single-centre, observational 2 year study conducted in IBD adult patients with stable disease treated with the originator infliximab who were switched to CT-P13. Four time points were defined for follow-up: prior to the switch, 4–8 weeks after the switch, 8 months later, and 2 years later. Outcome measures were the proportion of patients with clinical, endoscopic and biochemical remission, and changes in biochemical inflammation markers (albumin, C-reactive protein, faecal calprotectin) and infliximab clearance. <h3>Results</h3> 42 IBD patients were switched, of which 36 (85.7%) remained on CT-P13 throughout the 2 year study period. Only two patients discontinued CT-P13 due to loss of response. The proportion of patients who displayed clinical, endoscopic and biochemical remission were unchanged during the follow-up (p<0.05) and no statistically significant changes were observed in the biochemical markers of disease activity. The median (IQR) clearance estimated for the infliximab originator before the change was 0.364 (0.321–0.415) L/day, and for the CT-P13 biosimilar it was 0.361 (0.323–0.415) L/day 4–8 weeks after the change, and 0.370 (0.334–0.419) L/day 2 years after (p=0.395). <h3>Conclusion</h3> Switching from originator infliximab to biosimilar CT-P13 did not affect the long-term clinical outcomes or the pharmacokinetic behaviour. This information provides the clinician more evidence for the success of switching and supports non-medical switching in adult IBD patients." @default.
• W3095921647 created "2020-11-09" @default.
• W3095921647 creator A5001604985 @default.
• W3095921647 creator A5043135674 @default.
• W3095921647 creator A5070649080 @default.
• W3095921647 creator A5075951867 @default.
• W3095921647 creator A5077550825 @default.
• W3095921647 creator A5091333357 @default.
• W3095921647 date "2020-10-28" @default.
• W3095921647 modified "2023-10-18" @default.
• W3095921647 title "Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease" @default.
• W3095921647 cites W1967570746 @default.
• W3095921647 cites W1997156788 @default.
• W3095921647 cites W2003835888 @default.
• W3095921647 cites W2054580584 @default.
• W3095921647 cites W2121050884 @default.
• W3095921647 cites W2162768160 @default.
• W3095921647 cites W2175886073 @default.
• W3095921647 cites W2315907897 @default.
• W3095921647 cites W2463270817 @default.
• W3095921647 cites W2523706394 @default.
• W3095921647 cites W2587787178 @default.
• W3095921647 cites W2613299853 @default.
• W3095921647 cites W2751387666 @default.
• W3095921647 cites W2774116866 @default.
• W3095921647 cites W2795103548 @default.
• W3095921647 cites W2806215443 @default.
• W3095921647 cites W2841623998 @default.
• W3095921647 cites W2896737472 @default.
• W3095921647 cites W2912610515 @default.
• W3095921647 cites W2913878532 @default.
• W3095921647 cites W2923675504 @default.
• W3095921647 cites W2938260764 @default.
• W3095921647 cites W2981768636 @default.
• W3095921647 cites W3003483890 @default.
• W3095921647 cites W3004803806 @default.
• W3095921647 cites W3023976924 @default.
• W3095921647 cites W4293251512 @default.
• W3095921647 doi "https://doi.org/10.1136/ejhpharm-2020-002410" @default.
• W3095921647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33115797" @default.
• W3095921647 hasPublicationYear "2020" @default.
• W3095921647 type Work @default.
• W3095921647 sameAs 3095921647 @default.
• W3095921647 citedByCount "2" @default.
• W3095921647 countsByYear W30959216472022 @default.
• W3095921647 crossrefType "journal-article" @default.
• W3095921647 hasAuthorship W3095921647A5001604985 @default.
• W3095921647 hasAuthorship W3095921647A5043135674 @default.
• W3095921647 hasAuthorship W3095921647A5070649080 @default.
• W3095921647 hasAuthorship W3095921647A5075951867 @default.
• W3095921647 hasAuthorship W3095921647A5077550825 @default.
• W3095921647 hasAuthorship W3095921647A5091333357 @default.
• W3095921647 hasBestOaLocation W30959216471 @default.
• W3095921647 hasConcept C112705442 @default.
• W3095921647 hasConcept C126322002 @default.
• W3095921647 hasConcept C23131810 @default.
• W3095921647 hasConcept C2777138892 @default.
• W3095921647 hasConcept C2778260677 @default.
• W3095921647 hasConcept C2778292693 @default.
• W3095921647 hasConcept C2779008522 @default.
• W3095921647 hasConcept C2779134260 @default.
• W3095921647 hasConcept C2780479503 @default.
• W3095921647 hasConcept C2908647359 @default.
• W3095921647 hasConcept C59491497 @default.
• W3095921647 hasConcept C71924100 @default.
• W3095921647 hasConcept C90924648 @default.
• W3095921647 hasConcept C99454951 @default.
• W3095921647 hasConceptScore W3095921647C112705442 @default.
• W3095921647 hasConceptScore W3095921647C126322002 @default.
• W3095921647 hasConceptScore W3095921647C23131810 @default.
• W3095921647 hasConceptScore W3095921647C2777138892 @default.
• W3095921647 hasConceptScore W3095921647C2778260677 @default.
• W3095921647 hasConceptScore W3095921647C2778292693 @default.
• W3095921647 hasConceptScore W3095921647C2779008522 @default.
• W3095921647 hasConceptScore W3095921647C2779134260 @default.
• W3095921647 hasConceptScore W3095921647C2780479503 @default.
• W3095921647 hasConceptScore W3095921647C2908647359 @default.
• W3095921647 hasConceptScore W3095921647C59491497 @default.
• W3095921647 hasConceptScore W3095921647C71924100 @default.
• W3095921647 hasConceptScore W3095921647C90924648 @default.
• W3095921647 hasConceptScore W3095921647C99454951 @default.
• W3095921647 hasLocation W30959216471 @default.
• W3095921647 hasLocation W30959216472 @default.
• W3095921647 hasLocation W30959216473 @default.
• W3095921647 hasOpenAccess W3095921647 @default.
• W3095921647 hasPrimaryLocation W30959216471 @default.
• W3095921647 hasRelatedWork W2088135039 @default.
• W3095921647 hasRelatedWork W2090228779 @default.
• W3095921647 hasRelatedWork W2161661686 @default.
• W3095921647 hasRelatedWork W2326791703 @default.
• W3095921647 hasRelatedWork W2406401379 @default.
• W3095921647 hasRelatedWork W2415541294 @default.
• W3095921647 hasRelatedWork W2586591127 @default.
• W3095921647 hasRelatedWork W2971987621 @default.
• W3095921647 hasRelatedWork W2982020561 @default.
• W3095921647 hasRelatedWork W3122917925 @default.
• W3095921647 isParatext "false" @default.
• W3095921647 isRetracted "false" @default.

• next